Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat plus Erlotinib in EGFR-mutated NSCLC
NCT00503971Phase 2Terminated
- Sponsor
- Fundación GECP
- Start
- May 2008
- Primary completion
- Dec 2011
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of vorinostat in non-small cell lung cancer (NSCLC), sponsored by Fundación GECP. Primary endpoints: Progression Free Survival Rate at 12 Weeks and Maximum Tolerated Dose at 24 weeks. Started May 2008; status: terminated.
02
Drugs
vorinostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00503971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00503971.